{"transactions":[{"id":1549809,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":3,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":4,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":5,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T00:47:21.000Z","date":"2024-04-03","kind":"sale","planned":true,"acquired":false,"shares":4149,"price":6.2,"value":25723.8,"ownership":{"direct":false,"nature":"By: Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $5.97 to $6.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (7) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":268573,"source":{"system":"sec-edgar","filing":"0001213900-24-030020","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390024030020/ownership.xml","form_type":"4"}},{"id":1549808,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":3,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":4,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":5,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T00:47:21.000Z","date":"2024-04-03","kind":"sale","planned":true,"acquired":false,"shares":30047,"price":6.2,"value":186291.4,"ownership":{"direct":false,"nature":"By: Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $5.97 to $6.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (7) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":1945015,"source":{"system":"sec-edgar","filing":"0001213900-24-030020","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390024030020/ownership.xml","form_type":"4"}},{"id":1549807,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":3,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":4,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":5,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T00:47:21.000Z","date":"2024-04-03","kind":"sale","planned":true,"acquired":false,"shares":103870,"price":6.2,"value":643994.0,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $5.97 to $6.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (7) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the General Partner of Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":4023741,"source":{"system":"sec-edgar","filing":"0001213900-24-030020","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390024030020/ownership.xml","form_type":"4"}},{"id":1549806,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":3,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":4,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":5,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T00:47:21.000Z","date":"2024-04-02","kind":"sale","planned":true,"acquired":false,"shares":3050,"price":6.65,"value":20282.5,"ownership":{"direct":false,"nature":"By: Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $6.50 to $6.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (6) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":272722,"source":{"system":"sec-edgar","filing":"0001213900-24-030020","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390024030020/ownership.xml","form_type":"4"}},{"id":1549805,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":3,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":4,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":5,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T00:47:21.000Z","date":"2024-04-02","kind":"sale","planned":true,"acquired":false,"shares":22084,"price":6.65,"value":146858.6,"ownership":{"direct":false,"nature":"By: Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $6.50 to $6.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (6) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":1975062,"source":{"system":"sec-edgar","filing":"0001213900-24-030020","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390024030020/ownership.xml","form_type":"4"}},{"id":1549804,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":3,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":4,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":5,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T00:47:21.000Z","date":"2024-04-02","kind":"sale","planned":true,"acquired":false,"shares":76346,"price":6.65,"value":507700.9,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $6.50 to $6.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (6) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the General Partner of Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":4127611,"source":{"system":"sec-edgar","filing":"0001213900-24-030020","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390024030020/ownership.xml","form_type":"4"}},{"id":1549803,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":3,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":4,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":5,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T00:47:21.000Z","date":"2024-04-01","kind":"sale","planned":true,"acquired":false,"shares":5451,"price":6.99,"value":38102.49,"ownership":{"direct":false,"nature":"By: Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $6.71 to $7.30, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":275772,"source":{"system":"sec-edgar","filing":"0001213900-24-030020","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390024030020/ownership.xml","form_type":"4"}},{"id":1549802,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":3,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":4,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":5,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T00:47:21.000Z","date":"2024-04-01","kind":"sale","planned":true,"acquired":false,"shares":39411,"price":6.99,"value":275482.89,"ownership":{"direct":false,"nature":"By: Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $6.71 to $7.30, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":1997146,"source":{"system":"sec-edgar","filing":"0001213900-24-030020","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390024030020/ownership.xml","form_type":"4"}},{"id":1549801,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":3,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":4,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":5,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T00:47:21.000Z","date":"2024-04-01","kind":"sale","planned":true,"acquired":false,"shares":136255,"price":6.99,"value":952422.45,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $6.71 to $7.30, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the General Partner of Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":4203957,"source":{"system":"sec-edgar","filing":"0001213900-24-030020","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390024030020/ownership.xml","form_type":"4"}},{"id":1704826,"issuer":{"id":15659,"kind":"organization","name":"IPI Legacy Liquidation Co","symbol":"IMPLQ"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-12-19T18:00:01.000Z","date":"2023-12-19","kind":"sale","planned":false,"acquired":false,"shares":28632,"price":0.08,"value":2290.56,"ownership":{"direct":false,"nature":"By: Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $0.10 to $0.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by Vivo Capital Surplus Fund VIII, L.P. Capital VIII, LLC is the General Partner of Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":280294,"source":{"system":"sec-edgar","filing":"0001213900-23-097043","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1628048/000121390023097043/ownership.xml","form_type":"4"}},{"id":1704825,"issuer":{"id":15659,"kind":"organization","name":"IPI Legacy Liquidation Co","symbol":"IMPLQ"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-12-19T18:00:01.000Z","date":"2023-12-19","kind":"sale","planned":false,"acquired":false,"shares":208657,"price":0.08,"value":16692.56,"ownership":{"direct":false,"nature":"By: Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $0.10 to $0.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":2029495,"source":{"system":"sec-edgar","filing":"0001213900-23-097043","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1628048/000121390023097043/ownership.xml","form_type":"4"}},{"id":1704824,"issuer":{"id":15659,"kind":"organization","name":"IPI Legacy Liquidation Co","symbol":"IMPLQ"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-12-19T18:00:01.000Z","date":"2023-12-18","kind":"sale","planned":false,"acquired":false,"shares":28682,"price":0.11,"value":3155.02,"ownership":{"direct":false,"nature":"By: Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $0.30 to $0.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by Vivo Capital Surplus Fund VIII, L.P. Capital VIII, LLC is the General Partner of Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":308926,"source":{"system":"sec-edgar","filing":"0001213900-23-097043","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1628048/000121390023097043/ownership.xml","form_type":"4"}},{"id":1704823,"issuer":{"id":15659,"kind":"organization","name":"IPI Legacy Liquidation Co","symbol":"IMPLQ"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-12-19T18:00:01.000Z","date":"2023-12-18","kind":"sale","planned":false,"acquired":false,"shares":209029,"price":0.11,"value":22993.19,"ownership":{"direct":false,"nature":"By: Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $0.30 to $0.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":2238152,"source":{"system":"sec-edgar","filing":"0001213900-23-097043","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1628048/000121390023097043/ownership.xml","form_type":"4"}},{"id":1704822,"issuer":{"id":15659,"kind":"organization","name":"IPI Legacy Liquidation Co","symbol":"IMPLQ"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-12-19T18:00:01.000Z","date":"2023-12-15","kind":"sale","planned":false,"acquired":false,"shares":12066,"price":0.29,"value":3499.14,"ownership":{"direct":false,"nature":"By: Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $0.44 to $0.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by Vivo Capital Surplus Fund VIII, L.P. Capital VIII, LLC is the General Partner of Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":337608,"source":{"system":"sec-edgar","filing":"0001213900-23-097043","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1628048/000121390023097043/ownership.xml","form_type":"4"}},{"id":1704821,"issuer":{"id":15659,"kind":"organization","name":"IPI Legacy Liquidation Co","symbol":"IMPLQ"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-12-19T18:00:01.000Z","date":"2023-12-15","kind":"sale","planned":false,"acquired":false,"shares":87934,"price":0.29,"value":25500.86,"ownership":{"direct":false,"nature":"By: Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $0.44 to $0.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":2447181,"source":{"system":"sec-edgar","filing":"0001213900-23-097043","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628048/000121390023097043/ownership.xml","form_type":"4"}},{"id":1731318,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":5,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":6,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":7,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-22T23:51:43.000Z","date":"2023-11-21","kind":"sale","planned":false,"acquired":false,"shares":1457,"price":0.9,"value":1311.3,"ownership":{"direct":false,"nature":"By: Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $0.90 to $0.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the General Partner of Vivo Opportunity Holdings, L.P. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":111662,"source":{"system":"sec-edgar","filing":"0001213900-23-089692","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390023089692/ownership.xml","form_type":"4"}},{"id":1731317,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":5,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":6,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":7,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-22T23:51:43.000Z","date":"2023-11-21","kind":"sale","planned":false,"acquired":false,"shares":236,"price":0.9,"value":212.4,"ownership":{"direct":false,"nature":"By: Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $0.90 to $0.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by Vivo Capital Surplus Fund VIII, L.P. Capital VIII, LLC is the General Partner of Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":269587,"source":{"system":"sec-edgar","filing":"0001213900-23-089692","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390023089692/ownership.xml","form_type":"4"}},{"id":1731316,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":5,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":6,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":7,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-22T23:51:43.000Z","date":"2023-11-21","kind":"sale","planned":false,"acquired":false,"shares":1707,"price":0.9,"value":1536.3,"ownership":{"direct":false,"nature":"By: Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $0.90 to $0.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":1952302,"source":{"system":"sec-edgar","filing":"0001213900-23-089692","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390023089692/ownership.xml","form_type":"4"}},{"id":1734699,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":5,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":6,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":7,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-21T02:09:11.000Z","date":"2023-11-20","kind":"sale","planned":false,"acquired":false,"shares":23443,"price":0.92,"value":21567.56,"ownership":{"direct":false,"nature":"By: Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $0.92 to $0.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (6) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the General Partner of Vivo Opportunity Holdings, L.P. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":113119,"source":{"system":"sec-edgar","filing":"0001213900-23-088909","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390023088909/ownership.xml","form_type":"4"}},{"id":1734698,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":5,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":6,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":7,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-21T02:09:11.000Z","date":"2023-11-20","kind":"sale","planned":false,"acquired":false,"shares":3792,"price":0.92,"value":3488.64,"ownership":{"direct":false,"nature":"By: Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $0.92 to $0.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (6) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by Vivo Capital Surplus Fund VIII, L.P. Capital VIII, LLC is the General Partner of Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":269823,"source":{"system":"sec-edgar","filing":"0001213900-23-088909","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390023088909/ownership.xml","form_type":"4"}},{"id":1734697,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":5,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":6,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":7,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-21T02:09:11.000Z","date":"2023-11-20","kind":"sale","planned":false,"acquired":false,"shares":27465,"price":0.92,"value":25267.8,"ownership":{"direct":false,"nature":"Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $0.92 to $0.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (6) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":1954009,"source":{"system":"sec-edgar","filing":"0001213900-23-088909","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390023088909/ownership.xml","form_type":"4"}},{"id":1734696,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":5,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":6,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":7,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-21T02:09:11.000Z","date":"2023-11-17","kind":"sale","planned":false,"acquired":false,"shares":7009,"price":0.93,"value":6518.37,"ownership":{"direct":false,"nature":"By: Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $0.93 to $0.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the General Partner of Vivo Opportunity Holdings, L.P. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":136562,"source":{"system":"sec-edgar","filing":"0001213900-23-088909","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390023088909/ownership.xml","form_type":"4"}},{"id":1734695,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":5,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":6,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":7,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-21T02:09:11.000Z","date":"2023-11-17","kind":"sale","planned":false,"acquired":false,"shares":1134,"price":0.93,"value":1054.62,"ownership":{"direct":false,"nature":"By: Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $0.93 to $0.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by Vivo Capital Surplus Fund VIII, L.P. Capital VIII, LLC is the General Partner of Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":273615,"source":{"system":"sec-edgar","filing":"0001213900-23-088909","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390023088909/ownership.xml","form_type":"4"}},{"id":1734694,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":5,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":6,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":7,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Comon Stock","published_at":"2023-11-21T02:09:11.000Z","date":"2023-11-17","kind":"sale","planned":false,"acquired":false,"shares":8211,"price":0.93,"value":7636.23,"ownership":{"direct":false,"nature":"By: Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $0.93 to $0.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":1981474,"source":{"system":"sec-edgar","filing":"0001213900-23-088909","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390023088909/ownership.xml","form_type":"4"}},{"id":1734693,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":5,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":6,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":7,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-21T02:09:11.000Z","date":"2023-11-16","kind":"sale","planned":false,"acquired":false,"shares":6429,"price":0.96,"value":6171.84,"ownership":{"direct":false,"nature":"By: Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $0.95 to $0.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (4) to this Form 4"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the General Partner of Vivo Opportunity Holdings, L.P. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":143571,"source":{"system":"sec-edgar","filing":"0001213900-23-088909","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390023088909/ownership.xml","form_type":"4"}},{"id":1734692,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":5,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":6,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":7,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-21T02:09:11.000Z","date":"2023-11-16","kind":"sale","planned":false,"acquired":false,"shares":1040,"price":0.96,"value":998.4,"ownership":{"direct":false,"nature":"By: Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $0.95 to $0.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (4) to this Form 4"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by Vivo Capital Surplus Fund VIII, L.P. Capital VIII, LLC is the General Partner of Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":274749,"source":{"system":"sec-edgar","filing":"0001213900-23-088909","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390023088909/ownership.xml","form_type":"4"}},{"id":1734691,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":5,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":6,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":7,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-21T02:09:11.000Z","date":"2023-11-16","kind":"sale","planned":false,"acquired":false,"shares":7531,"price":0.96,"value":7229.76,"ownership":{"direct":false,"nature":"By: Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $0.95 to $0.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (4) to this Form 4"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":1989685,"source":{"system":"sec-edgar","filing":"0001213900-23-088909","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390023088909/ownership.xml","form_type":"4"}},{"id":2076833,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":3,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":4,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":5,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-12-23T22:48:58.000Z","date":"2022-12-23","kind":"purchase","acquired":true,"shares":758620,"price":7.25,"value":5499995.0,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Gaurav Aggarwal, Hongbo Lu, Kevin Dai, Frank Kung and Michael Chang are managing members of Vivo Opportunity, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Opportunity Fund Holdings, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his or her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":4340212,"source":{"system":"sec-edgar","filing":"0001213900-22-082664","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390022082664/ownership.xml","form_type":"4"}},{"id":2163179,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":3,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":4,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":5,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-09-09T00:00:48.000Z","date":"2022-09-07","kind":"purchase","acquired":true,"shares":600000,"price":3.6,"value":2160000.0,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Gaurav Aggarwal, Hongbo Lu, Kevin Dai, Frank Kung and Michael Chang are managing members of Vivo Opportunity, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Opportunity Fund Holdings, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his or her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":3581592,"source":{"system":"sec-edgar","filing":"0001213900-22-054888","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390022054888/ownership.xml","form_type":"4"}},{"id":2184338,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":3,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":4,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":5,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-funded Warrants (right to buy)","published_at":"2022-08-17T00:44:38.000Z","date":"2022-08-16","kind":"purchase","acquired":true,"shares":1500000,"price":2.4199,"value":3629850.0,"ownership":{"direct":false,"nature":"By: Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The reporting person acquired 1,500,000 shares of Common Stock at $2.42 per share and 1,500,000 pre-funded warrants at $2.41990 per warrant in an underwritten offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The pre-funded warrants have no expiration date and are exercisable immediately, to the extent that after giving effect to such exercise the reporting person and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, no more than 4.99% of the outstanding shares of Common Stock of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The pre-funded warrants have no expiration date and are exercisable immediately, to the extent that after giving effect to such exercise the reporting person and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, no more than 4.99% of the outstanding shares of Common Stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Gaurav Aggarwal, Hongbo Lu, Kevin Dai, Frank Kung and Michael Chang are managing members of Vivo Opportunity, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Opportunity Fund Holdings, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his or her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":1500000,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":1500000},"source":{"system":"sec-edgar","filing":"0001213900-22-048763","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390022048763/ownership.xml","form_type":"4"}},{"id":2184337,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":3,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":4,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":5,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-08-17T00:44:38.000Z","date":"2022-08-16","kind":"purchase","acquired":true,"shares":1500000,"price":2.42,"value":3630000.0,"ownership":{"direct":false,"nature":"By: Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The reporting person acquired 1,500,000 shares of Common Stock at $2.42 per share and 1,500,000 pre-funded warrants at $2.41990 per warrant in an underwritten offering."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reporting person acquired 1,500,000 shares of Common Stock at $2.42 per share and 1,500,000 pre-funded warrants at $2.41990 per warrant in an underwritten offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Gaurav Aggarwal, Hongbo Lu, Kevin Dai, Frank Kung and Michael Chang are managing members of Vivo Opportunity, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Opportunity Fund Holdings, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his or her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":2981592,"source":{"system":"sec-edgar","filing":"0001213900-22-048763","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390022048763/ownership.xml","form_type":"4"}},{"id":2184336,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":3,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":4,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":5,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-08-17T00:44:38.000Z","date":"2022-08-15","kind":"purchase","acquired":true,"shares":1218,"price":2.99,"value":3641.82,"ownership":{"direct":false,"nature":"By: Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $2.96 to $3.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Gaurav Aggarwal, Hongbo Lu, Kevin Dai, Frank Kung and Michael Chang are managing members of Vivo Opportunity, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Opportunity Fund Holdings, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his or her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":1481592,"source":{"system":"sec-edgar","filing":"0001213900-22-048763","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390022048763/ownership.xml","form_type":"4"}},{"id":2184335,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":3,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":4,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":5,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-08-17T00:44:38.000Z","date":"2022-08-12","kind":"purchase","acquired":true,"shares":1123021,"price":2.98,"value":3346602.58,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $2.83 to $3.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (2) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Gaurav Aggarwal, Hongbo Lu, Kevin Dai, Frank Kung and Michael Chang are managing members of Vivo Opportunity, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Opportunity Fund Holdings, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his or her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":1480374,"source":{"system":"sec-edgar","filing":"0001213900-22-048763","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390022048763/ownership.xml","form_type":"4"}},{"id":2735866,"issuer":{"id":15659,"kind":"organization","name":"IPI Legacy Liquidation Co","symbol":"IMPLQ"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"5% Convertible Note due 2021","published_at":"2021-04-29T21:10:51.000Z","date":"2021-04-27","kind":"exercise","acquired":false,"price":0,"reported_value":165013.49,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The convertible promissory note was issued by the issuer on March 5, 2021 and the outstanding principal and accrued interest is automatically converted into shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering at $13.50 per share (90% of the IPO price)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The convertible promissory note was issued by the issuer on March 5, 2021 and the outstanding principal and accrued interest is automatically converted into shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering at $13.50 per share (90% of the IPO price)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Surplus Fund VIII, L.P. As the managing members of Vivo Capital VIII, LLC, Frank Kung, Edgar Engleman and Shan Fu share voting and dispositive power over the shares held by Vivo Capital Surplus Fund VIII, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":13.5,"expiration_date":"2021-12-31","underlying":"Common Stock","underlying_shares":12311},"source":{"system":"sec-edgar","filing":"0001213900-21-023652","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1628048/000121390021023652/ownership.xml","form_type":"4"}},{"id":2735865,"issuer":{"id":15659,"kind":"organization","name":"IPI Legacy Liquidation Co","symbol":"IMPLQ"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"5% Convertible Note due 2021","published_at":"2021-04-29T21:10:51.000Z","date":"2021-04-27","kind":"exercise","acquired":false,"price":0,"reported_value":1194785.75,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The convertible promissory note was issued by the issuer on March 5, 2021 and the outstanding principal and accrued interest is automatically converted into shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering at $13.50 per share (90% of the IPO price)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The convertible promissory note was issued by the issuer on March 5, 2021 and the outstanding principal and accrued interest is automatically converted into shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering at $13.50 per share (90% of the IPO price)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities reported herein are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. As the managing members of Vivo Capital VIII, LLC, Frank Kung, Edgar Engleman and Shan Fu share voting and dispositive power over the shares held by Vivo Capital Fund VIII, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":13.5,"expiration_date":"2021-12-31","underlying":"Common Stock","underlying_shares":89145},"source":{"system":"sec-edgar","filing":"0001213900-21-023652","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1628048/000121390021023652/ownership.xml","form_type":"4"}},{"id":2735864,"issuer":{"id":15659,"kind":"organization","name":"IPI Legacy Liquidation Co","symbol":"IMPLQ"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Redeemable Convertible Preferred Stock","published_at":"2021-04-29T21:10:51.000Z","date":"2021-04-27","kind":"exercise","acquired":false,"shares":713064,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series C-1, C-2, C-3 and D Redeemable Convertible Preferred Stock is automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one share of common stock for 16.37332 preferred shares basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series C-1, C-2, C-3 and D Redeemable Convertible Preferred Stock is automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one share of common stock for 16.37332 preferred shares basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series C-1, C-2, C-3 and D Redeemable Convertible Preferred Stock is automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one share of common stock for 16.37332 preferred shares basis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Surplus Fund VIII, L.P. As the managing members of Vivo Capital VIII, LLC, Frank Kung, Edgar Engleman and Shan Fu share voting and dispositive power over the shares held by Vivo Capital Surplus Fund VIII, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":43550},"source":{"system":"sec-edgar","filing":"0001213900-21-023652","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1628048/000121390021023652/ownership.xml","form_type":"4"}},{"id":2735863,"issuer":{"id":15659,"kind":"organization","name":"IPI Legacy Liquidation Co","symbol":"IMPLQ"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Redeemable Convertible Preferred Stock","published_at":"2021-04-29T21:10:51.000Z","date":"2021-04-27","kind":"exercise","acquired":false,"shares":5162969,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series C-1, C-2, C-3 and D Redeemable Convertible Preferred Stock is automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one share of common stock for 16.37332 preferred shares basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series C-1, C-2, C-3 and D Redeemable Convertible Preferred Stock is automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one share of common stock for 16.37332 preferred shares basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series C-1, C-2, C-3 and D Redeemable Convertible Preferred Stock is automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one share of common stock for 16.37332 preferred shares basis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities reported herein are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. As the managing members of Vivo Capital VIII, LLC, Frank Kung, Edgar Engleman and Shan Fu share voting and dispositive power over the shares held by Vivo Capital Fund VIII, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":315328},"source":{"system":"sec-edgar","filing":"0001213900-21-023652","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1628048/000121390021023652/ownership.xml","form_type":"4"}},{"id":2735862,"issuer":{"id":15659,"kind":"organization","name":"IPI Legacy Liquidation Co","symbol":"IMPLQ"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-3 Redeemable Convertible Preferred Stock","published_at":"2021-04-29T21:10:51.000Z","date":"2021-04-27","kind":"exercise","acquired":false,"shares":995714,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series C-1, C-2, C-3 and D Redeemable Convertible Preferred Stock is automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one share of common stock for 16.37332 preferred shares basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series C-1, C-2, C-3 and D Redeemable Convertible Preferred Stock is automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one share of common stock for 16.37332 preferred shares basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series C-1, C-2, C-3 and D Redeemable Convertible Preferred Stock is automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one share of common stock for 16.37332 preferred shares basis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Surplus Fund VIII, L.P. As the managing members of Vivo Capital VIII, LLC, Frank Kung, Edgar Engleman and Shan Fu share voting and dispositive power over the shares held by Vivo Capital Surplus Fund VIII, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":60813},"source":{"system":"sec-edgar","filing":"0001213900-21-023652","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1628048/000121390021023652/ownership.xml","form_type":"4"}},{"id":2735861,"issuer":{"id":15659,"kind":"organization","name":"IPI Legacy Liquidation Co","symbol":"IMPLQ"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-3 Redeemable Convertible Preferred Stock","published_at":"2021-04-29T21:10:51.000Z","date":"2021-04-27","kind":"exercise","acquired":false,"shares":7206216,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series C-1, C-2, C-3 and D Redeemable Convertible Preferred Stock is automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one share of common stock for 16.37332 preferred shares basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series C-1, C-2, C-3 and D Redeemable Convertible Preferred Stock is automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one share of common stock for 16.37332 preferred shares basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series C-1, C-2, C-3 and D Redeemable Convertible Preferred Stock is automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one share of common stock for 16.37332 preferred shares basis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities reported herein are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. As the managing members of Vivo Capital VIII, LLC, Frank Kung, Edgar Engleman and Shan Fu share voting and dispositive power over the shares held by Vivo Capital Fund VIII, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":440119},"source":{"system":"sec-edgar","filing":"0001213900-21-023652","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1628048/000121390021023652/ownership.xml","form_type":"4"}},{"id":2735860,"issuer":{"id":15659,"kind":"organization","name":"IPI Legacy Liquidation Co","symbol":"IMPLQ"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-2 Redeemable Convertible Preferred Stock","published_at":"2021-04-29T21:10:51.000Z","date":"2021-04-27","kind":"exercise","acquired":false,"shares":1073308,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series C-1, C-2, C-3 and D Redeemable Convertible Preferred Stock is automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one share of common stock for 16.37332 preferred shares basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series C-1, C-2, C-3 and D Redeemable Convertible Preferred Stock is automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one share of common stock for 16.37332 preferred shares basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series C-1, C-2, C-3 and D Redeemable Convertible Preferred Stock is automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one share of common stock for 16.37332 preferred shares basis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Surplus Fund VIII, L.P. As the managing members of Vivo Capital VIII, LLC, Frank Kung, Edgar Engleman and Shan Fu share voting and dispositive power over the shares held by Vivo Capital Surplus Fund VIII, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":65552},"source":{"system":"sec-edgar","filing":"0001213900-21-023652","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1628048/000121390021023652/ownership.xml","form_type":"4"}},{"id":2735859,"issuer":{"id":15659,"kind":"organization","name":"IPI Legacy Liquidation Co","symbol":"IMPLQ"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-2 Redeemable Convertible Preferred Stock","published_at":"2021-04-29T21:10:51.000Z","date":"2021-04-27","kind":"exercise","acquired":false,"shares":7772634,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series C-1, C-2, C-3 and D Redeemable Convertible Preferred Stock is automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one share of common stock for 16.37332 preferred shares basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series C-1, C-2, C-3 and D Redeemable Convertible Preferred Stock is automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one share of common stock for 16.37332 preferred shares basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series C-1, C-2, C-3 and D Redeemable Convertible Preferred Stock is automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one share of common stock for 16.37332 preferred shares basis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities reported herein are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. As the managing members of Vivo Capital VIII, LLC, Frank Kung, Edgar Engleman and Shan Fu share voting and dispositive power over the shares held by Vivo Capital Fund VIII, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":474713},"source":{"system":"sec-edgar","filing":"0001213900-21-023652","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1628048/000121390021023652/ownership.xml","form_type":"4"}},{"id":2735858,"issuer":{"id":15659,"kind":"organization","name":"IPI Legacy Liquidation Co","symbol":"IMPLQ"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-1 Redeemable Convertible Preferred Stock","published_at":"2021-04-29T21:10:51.000Z","date":"2021-04-27","kind":"exercise","acquired":false,"shares":1605711,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series C-1, C-2, C-3 and D Redeemable Convertible Preferred Stock is automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one share of common stock for 16.37332 preferred shares basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series C-1, C-2, C-3 and D Redeemable Convertible Preferred Stock is automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one share of common stock for 16.37332 preferred shares basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series C-1, C-2, C-3 and D Redeemable Convertible Preferred Stock is automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one share of common stock for 16.37332 preferred shares basis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Surplus Fund VIII, L.P. As the managing members of Vivo Capital VIII, LLC, Frank Kung, Edgar Engleman and Shan Fu share voting and dispositive power over the shares held by Vivo Capital Surplus Fund VIII, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":98068},"source":{"system":"sec-edgar","filing":"0001213900-21-023652","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1628048/000121390021023652/ownership.xml","form_type":"4"}},{"id":2735857,"issuer":{"id":15659,"kind":"organization","name":"IPI Legacy Liquidation Co","symbol":"IMPLQ"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-1 Redeemable Convertible Preferred Stock","published_at":"2021-04-29T21:10:51.000Z","date":"2021-04-27","kind":"exercise","acquired":false,"shares":11628174,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series C-1, C-2, C-3 and D Redeemable Convertible Preferred Stock is automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one share of common stock for 16.37332 preferred shares basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series C-1, C-2, C-3 and D Redeemable Convertible Preferred Stock is automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one share of common stock for 16.37332 preferred shares basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series C-1, C-2, C-3 and D Redeemable Convertible Preferred Stock is automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one share of common stock for 16.37332 preferred shares basis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities reported herein are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. As the managing members of Vivo Capital VIII, LLC, Frank Kung, Edgar Engleman and Shan Fu share voting and dispositive power over the shares held by Vivo Capital Fund VIII, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":710190},"source":{"system":"sec-edgar","filing":"0001213900-21-023652","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1628048/000121390021023652/ownership.xml","form_type":"4"}},{"id":2735856,"issuer":{"id":15659,"kind":"organization","name":"IPI Legacy Liquidation Co","symbol":"IMPLQ"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-29T21:10:51.000Z","date":"2021-04-27","kind":"purchase","acquired":true,"shares":69380,"price":15,"value":1040700.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Surplus Fund VIII, L.P. As the managing members of Vivo Capital VIII, LLC, Frank Kung, Edgar Engleman and Shan Fu share voting and dispositive power over the shares held by Vivo Capital Surplus Fund VIII, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein."}],"balance_after":349674,"source":{"system":"sec-edgar","filing":"0001213900-21-023652","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1628048/000121390021023652/ownership.xml","form_type":"4"}},{"id":2735855,"issuer":{"id":15659,"kind":"organization","name":"IPI Legacy Liquidation Co","symbol":"IMPLQ"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-29T21:10:51.000Z","date":"2021-04-27","kind":"purchase","acquired":true,"shares":505620,"price":15,"value":7584300.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities reported herein are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. As the managing members of Vivo Capital VIII, LLC, Frank Kung, Edgar Engleman and Shan Fu share voting and dispositive power over the shares held by Vivo Capital Fund VIII, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein."}],"balance_after":2535115,"source":{"system":"sec-edgar","filing":"0001213900-21-023652","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1628048/000121390021023652/ownership.xml","form_type":"4"}},{"id":2735854,"issuer":{"id":15659,"kind":"organization","name":"IPI Legacy Liquidation Co","symbol":"IMPLQ"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-29T21:10:51.000Z","date":"2021-04-27","kind":"exercise","acquired":true,"shares":12311,"price":13.5,"value":166198.5,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The convertible promissory note was issued by the issuer on March 5, 2021 and the outstanding principal and accrued interest is automatically converted into shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering at $13.50 per share (90% of the IPO price)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Surplus Fund VIII, L.P. As the managing members of Vivo Capital VIII, LLC, Frank Kung, Edgar Engleman and Shan Fu share voting and dispositive power over the shares held by Vivo Capital Surplus Fund VIII, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein."}],"balance_after":280294,"source":{"system":"sec-edgar","filing":"0001213900-21-023652","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1628048/000121390021023652/ownership.xml","form_type":"4"}},{"id":2735853,"issuer":{"id":15659,"kind":"organization","name":"IPI Legacy Liquidation Co","symbol":"IMPLQ"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-29T21:10:51.000Z","date":"2021-04-27","kind":"exercise","acquired":true,"shares":89145,"price":13.5,"value":1203457.5,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The convertible promissory note was issued by the issuer on March 5, 2021 and the outstanding principal and accrued interest is automatically converted into shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering at $13.50 per share (90% of the IPO price)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities reported herein are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. As the managing members of Vivo Capital VIII, LLC, Frank Kung, Edgar Engleman and Shan Fu share voting and dispositive power over the shares held by Vivo Capital Fund VIII, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein."}],"balance_after":2029495,"source":{"system":"sec-edgar","filing":"0001213900-21-023652","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1628048/000121390021023652/ownership.xml","form_type":"4"}},{"id":2735852,"issuer":{"id":15659,"kind":"organization","name":"IPI Legacy Liquidation Co","symbol":"IMPLQ"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-29T21:10:51.000Z","date":"2021-04-27","kind":"exercise","acquired":true,"shares":43550,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series C-1, C-2, C-3 and D Redeemable Convertible Preferred Stock is automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one share of common stock for 16.37332 preferred shares basis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Surplus Fund VIII, L.P. As the managing members of Vivo Capital VIII, LLC, Frank Kung, Edgar Engleman and Shan Fu share voting and dispositive power over the shares held by Vivo Capital Surplus Fund VIII, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein."}],"balance_after":267983,"source":{"system":"sec-edgar","filing":"0001213900-21-023652","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1628048/000121390021023652/ownership.xml","form_type":"4"}},{"id":2735851,"issuer":{"id":15659,"kind":"organization","name":"IPI Legacy Liquidation Co","symbol":"IMPLQ"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-29T21:10:51.000Z","date":"2021-04-27","kind":"exercise","acquired":true,"shares":315328,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series C-1, C-2, C-3 and D Redeemable Convertible Preferred Stock is automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one share of common stock for 16.37332 preferred shares basis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities reported herein are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. As the managing members of Vivo Capital VIII, LLC, Frank Kung, Edgar Engleman and Shan Fu share voting and dispositive power over the shares held by Vivo Capital Fund VIII, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein."}],"balance_after":1940350,"source":{"system":"sec-edgar","filing":"0001213900-21-023652","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1628048/000121390021023652/ownership.xml","form_type":"4"}},{"id":2735850,"issuer":{"id":15659,"kind":"organization","name":"IPI Legacy Liquidation Co","symbol":"IMPLQ"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-29T21:10:51.000Z","date":"2021-04-27","kind":"exercise","acquired":true,"shares":60813,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series C-1, C-2, C-3 and D Redeemable Convertible Preferred Stock is automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one share of common stock for 16.37332 preferred shares basis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Surplus Fund VIII, L.P. As the managing members of Vivo Capital VIII, LLC, Frank Kung, Edgar Engleman and Shan Fu share voting and dispositive power over the shares held by Vivo Capital Surplus Fund VIII, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein."}],"balance_after":224433,"source":{"system":"sec-edgar","filing":"0001213900-21-023652","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1628048/000121390021023652/ownership.xml","form_type":"4"}},{"id":2735849,"issuer":{"id":15659,"kind":"organization","name":"IPI Legacy Liquidation Co","symbol":"IMPLQ"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-29T21:10:51.000Z","date":"2021-04-27","kind":"exercise","acquired":true,"shares":440119,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series C-1, C-2, C-3 and D Redeemable Convertible Preferred Stock is automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one share of common stock for 16.37332 preferred shares basis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities reported herein are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. As the managing members of Vivo Capital VIII, LLC, Frank Kung, Edgar Engleman and Shan Fu share voting and dispositive power over the shares held by Vivo Capital Fund VIII, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein."}],"balance_after":1625022,"source":{"system":"sec-edgar","filing":"0001213900-21-023652","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1628048/000121390021023652/ownership.xml","form_type":"4"}},{"id":2735848,"issuer":{"id":15659,"kind":"organization","name":"IPI Legacy Liquidation Co","symbol":"IMPLQ"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-29T21:10:51.000Z","date":"2021-04-27","kind":"exercise","acquired":true,"shares":65552,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series C-1, C-2, C-3 and D Redeemable Convertible Preferred Stock is automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one share of common stock for 16.37332 preferred shares basis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Surplus Fund VIII, L.P. As the managing members of Vivo Capital VIII, LLC, Frank Kung, Edgar Engleman and Shan Fu share voting and dispositive power over the shares held by Vivo Capital Surplus Fund VIII, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein."}],"balance_after":163620,"source":{"system":"sec-edgar","filing":"0001213900-21-023652","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1628048/000121390021023652/ownership.xml","form_type":"4"}},{"id":2735847,"issuer":{"id":15659,"kind":"organization","name":"IPI Legacy Liquidation Co","symbol":"IMPLQ"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-29T21:10:51.000Z","date":"2021-04-27","kind":"exercise","acquired":true,"shares":474713,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series C-1, C-2, C-3 and D Redeemable Convertible Preferred Stock is automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one share of common stock for 16.37332 preferred shares basis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities reported herein are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. As the managing members of Vivo Capital VIII, LLC, Frank Kung, Edgar Engleman and Shan Fu share voting and dispositive power over the shares held by Vivo Capital Fund VIII, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein."}],"balance_after":1184903,"source":{"system":"sec-edgar","filing":"0001213900-21-023652","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1628048/000121390021023652/ownership.xml","form_type":"4"}},{"id":2735846,"issuer":{"id":15659,"kind":"organization","name":"IPI Legacy Liquidation Co","symbol":"IMPLQ"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-29T21:10:51.000Z","date":"2021-04-27","kind":"exercise","acquired":true,"shares":98068,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series C-1, C-2, C-3 and D Redeemable Convertible Preferred Stock is automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one share of common stock for 16.37332 preferred shares basis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Surplus Fund VIII, L.P. As the managing members of Vivo Capital VIII, LLC, Frank Kung, Edgar Engleman and Shan Fu share voting and dispositive power over the shares held by Vivo Capital Surplus Fund VIII, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein."}],"balance_after":98068,"source":{"system":"sec-edgar","filing":"0001213900-21-023652","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1628048/000121390021023652/ownership.xml","form_type":"4"}},{"id":2735845,"issuer":{"id":15659,"kind":"organization","name":"IPI Legacy Liquidation Co","symbol":"IMPLQ"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-29T21:10:51.000Z","date":"2021-04-27","kind":"exercise","acquired":true,"shares":710190,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series C-1, C-2, C-3 and D Redeemable Convertible Preferred Stock is automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one share of common stock for 16.37332 preferred shares basis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities reported herein are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. As the managing members of Vivo Capital VIII, LLC, Frank Kung, Edgar Engleman and Shan Fu share voting and dispositive power over the shares held by Vivo Capital Fund VIII, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein."}],"balance_after":710190,"source":{"system":"sec-edgar","filing":"0001213900-21-023652","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628048/000121390021023652/ownership.xml","form_type":"4"}},{"id":2739617,"issuer":{"id":15659,"kind":"organization","name":"IPI Legacy Liquidation Co","symbol":"IMPLQ"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"5% Convertible Note due 2021","published_at":"2021-04-26T18:24:08.000Z","date":"2021-04-22","kind":"other","acquired":true,"price":0,"reported_value":165013.49,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The convertible promissory note was issued by the issuer on March 5, 2021 and the outstanding principal and accrued interest will automatically convert into the number of shares of the Issuer's Common Stock set forth above upon the closing of the Issuer's initial public offering (the \"IPO\") at $13.50 per share (90% of the IPO price). The conversion price became fixed upon pricing of the issuer's IPO on April 22, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The convertible promissory note was issued by the issuer on March 5, 2021 and the outstanding principal and accrued interest will automatically convert into the number of shares of the Issuer's Common Stock set forth above upon the closing of the Issuer's initial public offering (the \"IPO\") at $13.50 per share (90% of the IPO price). The conversion price became fixed upon pricing of the issuer's IPO on April 22, 2021."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Surplus Fund VIII, L.P. As the managing members of Vivo Capital VIII, LLC, Frank Kung, Edgar Engleman and Shan Fu share voting and dispositive power over the shares held by Vivo Capital Surplus Fund VIII, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein."}],"derivative":{"expiration_date":"2021-12-31","underlying":"Common Stock","underlying_shares":12311},"source":{"system":"sec-edgar","filing":"0001213900-21-022935","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1628048/000121390021022935/ownership.xml","form_type":"4"}},{"id":2739616,"issuer":{"id":15659,"kind":"organization","name":"IPI Legacy Liquidation Co","symbol":"IMPLQ"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"5% Convertible Note due 2021","published_at":"2021-04-26T18:24:08.000Z","date":"2021-04-22","kind":"other","acquired":true,"price":0,"reported_value":1194785.75,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The convertible promissory note was issued by the issuer on March 5, 2021 and the outstanding principal and accrued interest will automatically convert into the number of shares of the Issuer's Common Stock set forth above upon the closing of the Issuer's initial public offering (the \"IPO\") at $13.50 per share (90% of the IPO price). The conversion price became fixed upon pricing of the issuer's IPO on April 22, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The convertible promissory note was issued by the issuer on March 5, 2021 and the outstanding principal and accrued interest will automatically convert into the number of shares of the Issuer's Common Stock set forth above upon the closing of the Issuer's initial public offering (the \"IPO\") at $13.50 per share (90% of the IPO price). The conversion price became fixed upon pricing of the issuer's IPO on April 22, 2021."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. As the managing members of Vivo Capital VIII, LLC, Frank Kung, Edgar Engleman and Shan Fu share voting and dispositive power over the shares held by Vivo Capital Fund VIII, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein."}],"derivative":{"expiration_date":"2021-12-31","underlying":"Common Stock","underlying_shares":89145},"source":{"system":"sec-edgar","filing":"0001213900-21-022935","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628048/000121390021022935/ownership.xml","form_type":"4"}},{"id":2872094,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"other","acquired":false,"shares":5655,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"The shares subject to this warrant were fully vested prior to exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. Edgar Engleman is one of three voting members of Vivo Capital VIII, LLC."}],"balance_after":0,"derivative":{"exercise_price":0.07,"expiration_date":"2028-07-26","underlying":"Common Stock","underlying_shares":5655},"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":28,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872093,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-2 Preferred Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"exercise","acquired":false,"shares":47718,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The Series C-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The Series C-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The Series C-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. Edgar Engleman is one of three voting members of Vivo Capital VIII, LLC."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":47718},"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":27,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872092,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-1 Preferred Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"exercise","acquired":false,"shares":43901,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The Series C-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Series C-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Series C-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. Edgar Engleman is one of three voting members of Vivo Capital VIII, LLC."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":43901},"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":26,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872091,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"exercise","acquired":false,"shares":150802,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. Edgar Engleman is one of three voting members of Vivo Capital VIII, LLC."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":150802},"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872090,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"other","acquired":false,"shares":40953,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"The shares subject to this warrant were fully vested prior to exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities reported herein are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. Edgar Engleman is one of three voting members of Vivo Capital VIII, LLC."}],"balance_after":0,"derivative":{"exercise_price":0.07,"expiration_date":"2028-07-26","underlying":"Common Stock","underlying_shares":40953},"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872089,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-2 Preferred Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"exercise","acquired":false,"shares":345568,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The Series C-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The Series C-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The Series C-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities reported herein are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. Edgar Engleman is one of three voting members of Vivo Capital VIII, LLC."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":345568},"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872088,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-1 Preferred Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"exercise","acquired":false,"shares":317922,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The Series C-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Series C-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Series C-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities reported herein are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. Edgar Engleman is one of three voting members of Vivo Capital VIII, LLC."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":317922},"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872087,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"exercise","acquired":false,"shares":1092080,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities reported herein are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. Edgar Engleman is one of three voting members of Vivo Capital VIII, LLC."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1092080},"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872086,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"other","acquired":false,"shares":17711,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vivo PANDA Fund, L.P."},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"The shares subject to this warrant were fully vested prior to exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein are held of record by Vivo PANDA Fund, L.P. (\"Vivo LP\"). Vivo Panda, LLC (\"Vivo LLC\") is the sole general partner of Vivo LP. Mahendra G. Shah, Ph.D. is one of four voting members of Vivo LLC."}],"balance_after":0,"derivative":{"exercise_price":0.07,"expiration_date":"2028-07-26","underlying":"Common Stock","underlying_shares":17711},"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872085,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"exercise","acquired":false,"shares":472296,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vivo PANDA Fund, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein are held of record by Vivo PANDA Fund, L.P. (\"Vivo LP\"). Vivo Panda, LLC (\"Vivo LLC\") is the sole general partner of Vivo LP. Mahendra G. Shah, Ph.D. is one of four voting members of Vivo LLC."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":472296},"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872084,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Preferred Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"exercise","acquired":false,"shares":944056,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vivo PANDA Fund, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of\nthe Issuer's initial public offering (the \"IPO\") and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of\nthe Issuer's initial public offering (the \"IPO\") and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of\nthe Issuer's initial public offering (the \"IPO\") and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein are held of record by Vivo PANDA Fund, L.P. (\"Vivo LP\"). Vivo Panda, LLC (\"Vivo LLC\") is the sole general partner of Vivo LP. Mahendra G. Shah, Ph.D. is one of four voting members of Vivo LLC."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":944056},"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872083,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"purchase","acquired":true,"shares":150000,"price":20,"value":3000000.0,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held of record by Vivo Opportunity Fund, L.P. (VOF). Vivo Opportunity, LLC is the general partner of VOF and has four managing members."}],"balance_after":150000,"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872082,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"purchase","acquired":true,"shares":24267,"price":20,"value":485340.0,"ownership":{"direct":false,"nature":"By Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. Edgar Engleman is one of three voting members of Vivo Capital VIII, LLC."}],"balance_after":275789,"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872081,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"sale","acquired":false,"shares":20,"price":20,"value":400.0,"ownership":{"direct":false,"nature":"By Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F10","text":"Upon closing of the Issuer's IPO, Vivo Capital Surplus Fund VIII, L.P. exercised a warrant to purchase 5,655 shares of the Issuer's Common Stock at an exercise price per share of $0.07. Vivo Capital Surplus Fund VIII, L.P. paid the exercise price on a cashless basis, resulting in the Issuer withholding 20 share subject to the warrant in order to pay the exercise price and issuing to Vivo Capital Surplus Fund VIII, L.P. the remaining 5,635 shares of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. Edgar Engleman is one of three voting members of Vivo Capital VIII, LLC."}],"balance_after":251522,"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872080,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"other","acquired":true,"shares":5655,"price":0.07,"value":395.85,"ownership":{"direct":false,"nature":"By Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. Edgar Engleman is one of three voting members of Vivo Capital VIII, LLC."}],"balance_after":251542,"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872079,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"exercise","acquired":true,"shares":47718,"ownership":{"direct":false,"nature":"By Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The Series C-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. Edgar Engleman is one of three voting members of Vivo Capital VIII, LLC."}],"balance_after":245887,"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872078,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"exercise","acquired":true,"shares":43901,"ownership":{"direct":false,"nature":"By Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The Series C-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. Edgar Engleman is one of three voting members of Vivo Capital VIII, LLC."}],"balance_after":198169,"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872077,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"exercise","acquired":true,"shares":150802,"ownership":{"direct":false,"nature":"By Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. Edgar Engleman is one of three voting members of Vivo Capital VIII, LLC."}],"balance_after":154268,"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872076,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"purchase","acquired":true,"shares":175733,"price":20,"value":3514660.0,"ownership":{"direct":false,"nature":"By Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities reported herein are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. Edgar Engleman is one of three voting members of Vivo Capital VIII, LLC."}],"balance_after":1997216,"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872075,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"sale","acquired":false,"shares":144,"price":20,"value":2880.0,"ownership":{"direct":false,"nature":"By Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"Upon closing of the Issuer's IPO, Vivo Capital Fund VIII, L.P. exercised a warrant to purchase 40,953 shares of the Issuer's Common Stock at an exercise price per share of $0.07. Vivo Capital Fund VIII, L.P. paid the exercise price on a cashless basis, resulting in the Issuer withholding 144 share subject to the warrant in order to pay the exercise price and issuing to Vivo Capital Fund VIII, L.P. the remaining 40,809 shares of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities reported herein are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. Edgar Engleman is one of three voting members of Vivo Capital VIII, LLC."}],"balance_after":1821483,"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872074,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"other","acquired":true,"shares":40953,"price":0.07,"value":2866.71,"ownership":{"direct":false,"nature":"By Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities reported herein are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. Edgar Engleman is one of three voting members of Vivo Capital VIII, LLC."}],"balance_after":1821627,"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872073,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"exercise","acquired":true,"shares":345568,"ownership":{"direct":false,"nature":"By Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The Series C-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities reported herein are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. Edgar Engleman is one of three voting members of Vivo Capital VIII, LLC."}],"balance_after":1780674,"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872072,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"exercise","acquired":true,"shares":317922,"ownership":{"direct":false,"nature":"By Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The Series C-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities reported herein are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. Edgar Engleman is one of three voting members of Vivo Capital VIII, LLC."}],"balance_after":1435106,"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872071,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"exercise","acquired":true,"shares":1092080,"ownership":{"direct":false,"nature":"By Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities reported herein are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. Edgar Engleman is one of three voting members of Vivo Capital VIII, LLC."}],"balance_after":1117184,"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872070,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"sale","acquired":false,"shares":62,"price":20,"value":1240.0,"ownership":{"direct":false,"nature":"By Vivo PANDA Fund, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Upon closing of the Issuer's IPO, Vivo LP exercised a warrant to purchase 17,711 shares of the Issuer's Common Stock at an exercise price per share of $0.07. Vivo LP paid the exercise price on a cashless basis, resulting in the Issuer withholding 62 share subject to the warrant in order to pay the exercise price and issuing to Vivo LP the remaining 17,649 shares of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein are held of record by Vivo PANDA Fund, L.P. (\"Vivo LP\"). Vivo Panda, LLC (\"Vivo LLC\") is the sole general partner of Vivo LP. Mahendra G. Shah, Ph.D. is one of four voting members of Vivo LLC."}],"balance_after":1448286,"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872069,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"other","acquired":true,"shares":17711,"price":0.07,"value":1239.77,"ownership":{"direct":false,"nature":"By Vivo PANDA Fund, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein are held of record by Vivo PANDA Fund, L.P. (\"Vivo LP\"). Vivo Panda, LLC (\"Vivo LLC\") is the sole general partner of Vivo LP. Mahendra G. Shah, Ph.D. is one of four voting members of Vivo LLC."}],"balance_after":1448348,"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872068,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"exercise","acquired":true,"shares":472296,"ownership":{"direct":false,"nature":"By Vivo PANDA Fund, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein are held of record by Vivo PANDA Fund, L.P. (\"Vivo LP\"). Vivo Panda, LLC (\"Vivo LLC\") is the sole general partner of Vivo LP. Mahendra G. Shah, Ph.D. is one of four voting members of Vivo LLC."}],"balance_after":1430637,"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872067,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"exercise","acquired":true,"shares":944056,"ownership":{"direct":false,"nature":"By Vivo PANDA Fund, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of\nthe Issuer's initial public offering (the \"IPO\") and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein are held of record by Vivo PANDA Fund, L.P. (\"Vivo LP\"). Vivo Panda, LLC (\"Vivo LLC\") is the sole general partner of Vivo LP. Mahendra G. Shah, Ph.D. is one of four voting members of Vivo LLC."}],"balance_after":958341,"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872066,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":5,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2021-02-09T20:08:19.000Z","date":"2021-02-09","kind":"exercise","acquired":false,"shares":50282,"ownership":{"direct":false,"nature":"Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each share of Series C Preferred Stock automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of Series C Preferred Stock automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each share of Series C Preferred Stock automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each share of Series C Preferred Stock automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Capital VIII, LLC (\"Vivo LLC\") is the general partner of each of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P., the record holder of the securities. Dr. Hongbo Lu is a Managing Partner at Vivo Capital LLC and a member of the Issuer's board of directors. Frank Kung, Edgar Engleman and Shan Fu are managing members of Vivo LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":50282},"source":{"system":"sec-edgar","filing":"0001567619-21-002591","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000156761921002591/doc1.xml","form_type":"4"}},{"id":2872065,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":5,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2021-02-09T20:08:19.000Z","date":"2021-02-09","kind":"exercise","acquired":false,"shares":364138,"ownership":{"direct":false,"nature":"Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each share of Series C Preferred Stock automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of Series C Preferred Stock automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each share of Series C Preferred Stock automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each share of Series C Preferred Stock automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Capital VIII, LLC (\"Vivo LLC\") is the general partner of each of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P., the record holder of the securities. Dr. Hongbo Lu is a Managing Partner at Vivo Capital LLC and a member of the Issuer's board of directors. Frank Kung, Edgar Engleman and Shan Fu are managing members of Vivo LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":364138},"source":{"system":"sec-edgar","filing":"0001567619-21-002591","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000156761921002591/doc1.xml","form_type":"4"}},{"id":2872064,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":5,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-02-09T20:08:19.000Z","date":"2021-02-09","kind":"exercise","acquired":false,"shares":98484,"ownership":{"direct":false,"nature":"Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Preferred Stock automatically converted on a 1-for-2.2 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock automatically converted on a 1-for-2.2 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Preferred Stock automatically converted on a 1-for-2.2 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Preferred Stock automatically converted on a 1-for-2.2 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Capital VIII, LLC (\"Vivo LLC\") is the general partner of each of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P., the record holder of the securities. Dr. Hongbo Lu is a Managing Partner at Vivo Capital LLC and a member of the Issuer's board of directors. Frank Kung, Edgar Engleman and Shan Fu are managing members of Vivo LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":216666},"source":{"system":"sec-edgar","filing":"0001567619-21-002591","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000156761921002591/doc1.xml","form_type":"4"}},{"id":2872063,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":5,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-02-09T20:08:19.000Z","date":"2021-02-09","kind":"exercise","acquired":false,"shares":713203,"ownership":{"direct":false,"nature":"Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Preferred Stock automatically converted on a 1-for-2.2 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock automatically converted on a 1-for-2.2 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Preferred Stock automatically converted on a 1-for-2.2 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Preferred Stock automatically converted on a 1-for-2.2 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Capital VIII, LLC (\"Vivo LLC\") is the general partner of each of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P., the record holder of the securities. Dr. Hongbo Lu is a Managing Partner at Vivo Capital LLC and a member of the Issuer's board of directors. Frank Kung, Edgar Engleman and Shan Fu are managing members of Vivo LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1569047},"source":{"system":"sec-edgar","filing":"0001567619-21-002591","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000156761921002591/doc1.xml","form_type":"4"}},{"id":2872062,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":5,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:08:19.000Z","date":"2021-02-09","kind":"purchase","acquired":true,"shares":357353,"price":17,"value":6075001.0,"ownership":{"direct":false,"nature":"Vivo Opportunity Fund, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund, L.P.   Gaurav Aggarwal, Shan Fu, Frank Kung and Michael Chang are managing members of Vivo Opportunity, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Opportunity Fund, L.P.  Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":357353,"source":{"system":"sec-edgar","filing":"0001567619-21-002591","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000156761921002591/doc1.xml","form_type":"4"}},{"id":2872061,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":5,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:08:19.000Z","date":"2021-02-09","kind":"purchase","acquired":true,"shares":14275,"price":17,"value":242675.0,"ownership":{"direct":false,"nature":"Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Capital VIII, LLC (\"Vivo LLC\") is the general partner of each of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P., the record holder of the securities. Dr. Hongbo Lu is a Managing Partner at Vivo Capital LLC and a member of the Issuer's board of directors. Frank Kung, Edgar Engleman and Shan Fu are managing members of Vivo LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":281223,"source":{"system":"sec-edgar","filing":"0001567619-21-002591","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000156761921002591/doc1.xml","form_type":"4"}},{"id":2872060,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":5,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:08:19.000Z","date":"2021-02-09","kind":"purchase","acquired":true,"shares":103372,"price":17,"value":1757324.0,"ownership":{"direct":false,"nature":"Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Capital VIII, LLC (\"Vivo LLC\") is the general partner of each of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P., the record holder of the securities. Dr. Hongbo Lu is a Managing Partner at Vivo Capital LLC and a member of the Issuer's board of directors. Frank Kung, Edgar Engleman and Shan Fu are managing members of Vivo LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":2036557,"source":{"system":"sec-edgar","filing":"0001567619-21-002591","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000156761921002591/doc1.xml","form_type":"4"}},{"id":2872059,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":5,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:08:19.000Z","date":"2021-02-09","kind":"exercise","acquired":true,"shares":266948,"ownership":{"direct":false,"nature":"Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock automatically converted on a 1-for-2.2 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of Series C Preferred Stock automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Capital VIII, LLC (\"Vivo LLC\") is the general partner of each of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P., the record holder of the securities. Dr. Hongbo Lu is a Managing Partner at Vivo Capital LLC and a member of the Issuer's board of directors. Frank Kung, Edgar Engleman and Shan Fu are managing members of Vivo LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":266948,"source":{"system":"sec-edgar","filing":"0001567619-21-002591","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000156761921002591/doc1.xml","form_type":"4"}},{"id":2872058,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":5,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:08:19.000Z","date":"2021-02-09","kind":"exercise","acquired":true,"shares":1933185,"ownership":{"direct":false,"nature":"Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock automatically converted on a 1-for-2.2 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of Series C Preferred Stock automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Capital VIII, LLC (\"Vivo LLC\") is the general partner of each of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P., the record holder of the securities. Dr. Hongbo Lu is a Managing Partner at Vivo Capital LLC and a member of the Issuer's board of directors. Frank Kung, Edgar Engleman and Shan Fu are managing members of Vivo LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":1933185,"source":{"system":"sec-edgar","filing":"0001567619-21-002591","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000156761921002591/doc1.xml","form_type":"4"}},{"id":3003108,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-2 Preferred Stock","published_at":"2020-10-20T20:59:25.000Z","date":"2020-10-20","kind":"exercise","acquired":false,"shares":30939,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Capital VIII, LLC (\"Vivo LLC\") is the general partner of each of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P., the record holder of the securities.  Frank Kung, Edgar Engleman and Shan Fu are managing members of Vivo LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed ad admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":30939},"source":{"system":"sec-edgar","filing":"0001567619-20-018010","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761920018010/doc1.xml","form_type":"4"}},{"id":3003107,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-2 Preferred Stock","published_at":"2020-10-20T20:59:25.000Z","date":"2020-10-20","kind":"exercise","acquired":false,"shares":224054,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Capital VIII, LLC (\"Vivo LLC\") is the general partner of each of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P., the record holder of the securities.  Frank Kung, Edgar Engleman and Shan Fu are managing members of Vivo LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed ad admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":224054},"source":{"system":"sec-edgar","filing":"0001567619-20-018010","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761920018010/doc1.xml","form_type":"4"}},{"id":3003106,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Preferred Stock","published_at":"2020-10-20T20:59:25.000Z","date":"2020-10-20","kind":"exercise","acquired":false,"shares":72320,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Capital VIII, LLC (\"Vivo LLC\") is the general partner of each of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P., the record holder of the securities.  Frank Kung, Edgar Engleman and Shan Fu are managing members of Vivo LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed ad admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":72320},"source":{"system":"sec-edgar","filing":"0001567619-20-018010","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761920018010/doc1.xml","form_type":"4"}},{"id":3003105,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Preferred Stock","published_at":"2020-10-20T20:59:25.000Z","date":"2020-10-20","kind":"exercise","acquired":false,"shares":523726,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Capital VIII, LLC (\"Vivo LLC\") is the general partner of each of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P., the record holder of the securities.  Frank Kung, Edgar Engleman and Shan Fu are managing members of Vivo LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed ad admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":523726},"source":{"system":"sec-edgar","filing":"0001567619-20-018010","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761920018010/doc1.xml","form_type":"4"}},{"id":3003104,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-10-20T20:59:25.000Z","date":"2020-10-20","kind":"exercise","acquired":false,"shares":260380,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Capital VIII, LLC (\"Vivo LLC\") is the general partner of each of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P., the record holder of the securities.  Frank Kung, Edgar Engleman and Shan Fu are managing members of Vivo LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed ad admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":260380},"source":{"system":"sec-edgar","filing":"0001567619-20-018010","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761920018010/doc1.xml","form_type":"4"}},{"id":3003103,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-10-20T20:59:25.000Z","date":"2020-10-20","kind":"exercise","acquired":false,"shares":1885611,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Capital VIII, LLC (\"Vivo LLC\") is the general partner of each of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P., the record holder of the securities.  Frank Kung, Edgar Engleman and Shan Fu are managing members of Vivo LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed ad admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1885611},"source":{"system":"sec-edgar","filing":"0001567619-20-018010","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761920018010/doc1.xml","form_type":"4"}}],"next_cursor":"2020-10-20T20:59:25.000000Z,3003103"}